---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091744"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:39:21.852769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics posts Q2 net loss of $13.4M; announces ProGen partnership for oral obesity drug RT-114

## Summary
- Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.
- Net loss of $13.4M for Q2 2024, compared to $18.7M in same period 2023; includes $4.1M stock-based compensation.
- R&D expenses fell to $6.1M from $11.1M YoY, driven by workforce reduction and timing of preclinical/clinical studies.
- Announced co-development partnership with ProGen for RT-114, an oral GLP-1/GLP-2 dual agonist, with 50/50 cost and revenue share.
- Phase 1 study for RT-114 expected to start in 2025; completed $10.0M equity offering in July 2024.

## SEC filing metadata
- accession: 0000950170-24-091744
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/0000950170-24-091744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017024091744/rani-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091744
- JSON: https://secwatch.observer/filing/0000950170-24-091744.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.